arrow
İ

İlkay Tuğba Ünek

dokuz eylul university faculty of medicine
H指数:10
被引数:380

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI-SAFRADJU-2501)

切除后胆道癌的辅助化疗方案:国家性、比较性、观察性研究(TOG/GI-SAFRADJU-2501)

2026-08-150
OAAI
First-Line Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey

一线度伐利尤单抗–特瑞普利单抗治疗晚期肝细胞癌:来自土耳其的真实世界数据

2026-08-020
OA
Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group

BRAF阴性转移性黑色素瘤患者在接受纳武利尤单抗治疗后进展的实体世界治疗结果:土耳其肿瘤学小组进行的多中心队列研究

2026-07-040
OA
Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors-A Turkish Oncology Group Study
CANCERS
IF4.4
2025-12-290
OA
SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab

SUVmax-IPI 作为一种新的预后指数,在接收Nivolumab治疗的转移性非小细胞肺癌患者中的应用

2025-10-090
OAAI
Comparison of Total Mesopancreatic Excision and Conventional Pancreaticoduodenectomy in the Surgical Treatment of Pancreatic Head Adenocarcinoma: Early Postoperative Outcomes

比较全_mesopancreatic_切除与常规胰腺十二指肠切除术在胰头腺癌手术治疗中的早期术后结果

2025-09-230
OAAI
Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)

比较一线FOLFIRINOX与基于氟尿嘧啶和基于吉西他滨的化疗在转移性壶腹腺癌中的疗效:一项由土耳其肿瘤学组(TOG)进行的多中心研究

2025-08-230
PRE
FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)

FOLFIRINOX:胰腺导管腺癌的最佳辅助治疗?土耳其肿瘤学组(TOG)的多中心研究

2025-08-220
PRE
Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma

辅助治疗方式对根治性切除的胰腺和壶腹周围腺癌的生存结局的影响

2015-08-012
PRE